Loading company…
Sling Therapeutics develops oral treatments for thyroid eye disease and other disorders.
Founded in 2020, Sling Therapeutics is based in Ann Arbor, US, and develops biopharmaceutical treatments. Its oral drug linsitinib is in a Phase 2b study for thyroid eye disease and blocks the IGF-1R target. In September 2026, the company raised USD 123 million in Series C funding led by Forbion, with participation from Sectoral Asset Management and TPG, to support late-stage clinical development and a pivotal trial.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in